European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

GALAXY: Gut-and-liver axis in alcoholic liver fibrosis

Descripción del proyecto

Microbiota intestinal: diana terapéutica para la fibrosis hepática alcohólica?

El consumo excesivo de bebidas alcohólicas puede provocar acumulación de grasa en el hígado, inflamación y daños, que causan hepatopatía alcohólica. Si se detecta y trata a tiempo, la fibrosis hepática alcohólica puede revertirse. En el proyecto GALAXY, financiado con fondos europeos, se trabajará bajo la hipótesis de que la interacción entre el microbioma intestinal y el hígado desempeña un papel fundamental en el desarrollo y la progresión de la fibrosis hepática alcohólica. Sus investigadores estudiarán la compleja interacción entre la microbiota intestinal y el hígado, identificarán biomarcadores y desarrollarán estrategias sanitarias personalizadas para las personas en situación de riesgo. El objetivo es modular la microbiota intestinal para prevenir y mitigar la fibrosis hepática alcohólica, lo que proporcionará evidentes beneficios socioeconómicos.

Objetivo

Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of liver cirrhosis, which is the 5th and 7th most common cause of life years lost in respectively Eastern and Western Europe. Cirrhosis is considered irreversible but its precursor, liver fibrosis, is reversible when detected before disease progression. GALAXY proposes that crosstalk between the gut microbiome and the liver influences the development and progression of alcoholic liver fibrosis. Here, a ‘dysbiotic’ microbiome in susceptible individuals leads to progressive liver fibrosis in combination with alcohol overuse. Therefore, interventions aiming to restore a healthy gut microbiome will reduce disease development. We will use state-of-the-art systems medicine tools to improve understanding of the complex interplay present during alcoholic liver fibrosis, to identify at-risk individuals in time and to develop personalised healthcare strategies for alcohol over-users (20% of the EU population >15 years old). GALAXY brings together partners with unique research competences in clinical hepatology, microbiome, multi-omics, biomarkers and bioinformatics. Our aim is to develop novel systems medicine tools which integrate clinical, multi-omics and lifestyle information from alcohol over-users at various stages of the disease and healthy individuals in order to: 1) identify signatures of host-microbial cross-talk during disease development and progression, 2) translate this into biomarkers for diagnosis, stratification and treatment monitoring in alcohol over users, and 3) evaluate new interventions to modulate gut microbiota towards prevention and mitigation of the disease in at-risk individuals. We will also study societal and economic impact of GALAXY biomarkers and treatments to accelerate future development. The GALAXY consortium includes strong SME partners who will enable the results to be exploited commercially.

Convocatoria de propuestas

H2020-PHC-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-PHC-2015-two-stage

Régimen de financiación

RIA - Research and Innovation action

Coordinador

SYDDANSK UNIVERSITET
Aportación neta de la UEn
€ 639 843,00
Dirección
CAMPUSVEJ 55
5230 Odense M
Dinamarca

Ver en el mapa

Región
Danmark Syddanmark Fyn
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 639 843,75

Participantes (12)